Eventide Asset Management’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Eventide Asset Management’s Portfolio RPTP Stock Details RPTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-16,000	Closed	-$253K	–	146
2015 Q2	$253K	Sell	16,000 -14,000	-47%	-$170K	0.01%	108
2015 Q1	$326K	Hold	30,000	–	–	0.02%	108
2014 Q4	$316K	Sell	30,000 -10,400	-26%	-$102K	0.03%	103
2014 Q3	$387K	Hold	40,400	–	–	0.05%	102
2014 Q2	$467K	Hold	40,400	–	–	0.06%	102
2014 Q1	$404K	Hold	40,400	–	–	0.06%	100
2013 Q4	$526K	Buy	+40,400	New	+$556K	0.16%	82

Other funds holding RPTP

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Eventide Asset Management's RPTP Position: Q3 2015 in Review

Eventide Asset Management sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q3 2015, closing a stake of 16,000 shares — an estimated $253K sold.

Eventide Asset Management first reported a position in RPTP in Q4 2013 and held it in 7 quarters. The position peaked at $526K in Q4 2013. 106 funds tracked by Wall St. Rank hold RPTP as of Q3 2015.

Eventide Asset Management reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q3 2015 after selling out during the quarter.
Eventide Asset Management sold 16,000 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q3 2015, an estimated $253K.
Eventide Asset Management first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q4 2013 and held it in 7 quarters.
Eventide Asset Management's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $526K in Q4 2013.
106 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q3 2015.

Based on Eventide Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.